Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial
Conditions
Interventions
rhTPO
eltrombopag
Locations
1
China
Zhou Yiming
Wuhan, Hubei, China
Start Date
January 16, 2019
Primary Completion Date
May 1, 2020
Completion Date
May 15, 2020
Last Updated
November 15, 2019
NCT05070845
NCT07039422
NCT06888960
NCT06594146
NCT07421167
NCT07083739
Lead Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions